Compare · HYPD vs NVS
HYPD vs NVS
Side-by-side comparison of Hyperion DeFi Inc. (HYPD) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HYPD and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $293.40B, about 7064.3x HYPD ($41.5M).
- Over the past year, HYPD is down 78.5% and NVS is up 34.6% - NVS leads by 113.1 points.
- HYPD has been more active in the news (9 items in the past 4 weeks vs 1 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 2 for HYPD).
- Company
- Hyperion DeFi Inc.
- Novartis AG
- Price
- -
- -
- Market cap
- $41.5M
- $293.40B
- 1M return
- -14.15%
- +1.89%
- 1Y return
- -78.48%
- +34.60%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 9
- 1
- Recent ratings
- 2
- 25
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest HYPD
- Hyperion DeFi Enters Agreement with Skew Technologies to Launch HIP-3 Perpetual Futures Market and Listing Service
- Hyperion DeFi Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Director Walters Happy David was granted 58,917 shares, increasing direct ownership by 53% to 170,847 units (SEC Form 4)
- Director Strahlman Ellen R was granted 58,917 shares, increasing direct ownership by 65% to 150,078 units (SEC Form 4)
- Director Jacobson Rachel was granted 58,917 shares, increasing direct ownership by 105% to 115,218 units (SEC Form 4)
- Director Geltzeiler Michael S was granted 58,917 shares, increasing direct ownership by 67% to 146,932 units (SEC Form 4)
- Hyperion DeFi Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Amendment: SEC Form SCHEDULE 13G/A filed by Hyperion DeFi Inc.
- Hyperion DeFi and Blockdaemon Partner to Expand Institutional Hyperliquid Staking Infrastructure
- Hyperion DeFi Reiterates Guidance on Sunset of USDH and Felix Markets
Latest NVS
- The Quest to Repair What Multiple Sclerosis Takes Away
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG